




SOLIQUA[®]

insulin glargine & lixisenatide injection



- **2 ACTIVE INGREDIENTS:**
insulin glargine
and lixisenatide
- **1 FIXED RATIO
COMBINATION** therapy
- **ONCE-DAILY** injection*

NOW REIMBURSED AS A GENERAL BENEFIT UNDER THE ODB FORMULARY

See reverse for details.

SOLIQUA[®], a fixed ratio combination of insulin glargine and lixisenatide, once-daily injection, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus inadequately controlled on basal insulin (<60 units daily) alone or in combination with metformin.¹

ODB=Ontario Drug Benefit.

* Refer to the Product Monograph for complete dosing and administration information.

ODB REIMBURSEMENT CRITERIA

SOLIQUA[®] – As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus inadequately controlled on basal insulin (<60 units daily) in combination with metformin.²

Consult the Product Monograph at <http://products.sanofi.ca/en/soliqua.pdf> for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1.888.852.6887.

References: 1. SOLIQUA[®] Product Monograph, sanofi-aventis Canada Inc., July 6, 2018. 2. Ontario Drug Benefit Formulary/Comparative Drug Index. Edition 43. Drug Programs Policy and Strategy Branch, Drugs and Devices Division, Ministry of Health. Summary of changes – December 2019.

Copyright © 2020 sanofi-aventis Canada Inc.
All rights reserved.

SACA.LALI.20.01.0013

